Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases.

Jansen, Yanina J L; Verset, Gontran; Schats, Kelly; Van Dam, Pieter-Jan; Seremet, Teofila; Kockx, Mark; Van Laethem, Jean-Luc B; Neyns, Bart

Jansen, Yanina J L; Verset, Gontran; Schats, Kelly; Van Dam, Pieter-Jan; Seremet, Teofila; Kockx, Mark; Van Laethem, Jean-Luc B; Neyns, Bart.

Affiliation

Jansen YJL; Oncology, Universitair ziekenhuis Brussel, Brussel, Belgium.
Verset G; Oncology, Hopital Erasme, Bruxelles, Belgium.
Schats K; Anatomopathology, Histogenex, Antwerp, Belgium.
Van Dam PJ; HistoGeneX NV, Edegem, Belgium.
Seremet T; Oncology, Universitair ziekenhuis Brussel, Brussel, Belgium.
Kockx M; HistoGeneX NV, Edegem, Belgium.
Van Laethem JB; Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Neyns B; Oncology, Universitair ziekenhuis Brussel, Brussel, Belgium.

ESMO Open ; 4(2): e000464, 2019.

Article in En | MEDLINE | ID: mdl-30962963

Key words

decitabine; hepatic arterial infusion; liver metastases

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: ESMO Open Year: 2019 Type: Article Affiliation country: Belgium

Fulltext

XML

PubMed Links

Search on Google